Literature DB >> 25196428

Airway bacterial colonization and serum C-reactive protein are associated with chronic obstructive pulmonary disease exacerbation following bronchoscopic lung volume reduction.

Oren Fruchter1,2, Dror Rosengarten1,2, Elad Goldberg2,3, Haim Ben-Zvi2,4, Ruth Tor2,4, Mordechai R Kramer1,2.   

Abstract

INTRODUCTION: Stable chronic obstructive pulmonary disease (COPD) patients often have lower airway bacterial colonization (ABC) which may modulate exacerbation frequency. Data regarding the association between ABC and post-procedural COPD exacerbations following bronchoscopic lung volume reduction (BLVR) are scant.
OBJECTIVES: Our aim was to explore the correlation among ABC, serum C-reactive protein (CRP) level and the risk of COPD exacerbation within a month following BLVR.
METHODS: Pre-procedure bronchoalveolar lavage (BAL) quantitative bacterial cultures and serum levels of CRP were evaluated in severe COPD patients (N = 70, mean FEV1  = 34.6%) before BLVR by polymeric lung sealant.
RESULTS: Colonization with potential pathogenic microorganism (PPM) was observed in 40 (57.1%) patients. Out of 28 patients (40%) who had COPD exacerbation within 30 days of BLVR, 23 (82.1%) had PPM in BAL culture compared with only 14 (33.3%) out of 42 patients who had uneventful procedure (P = 0.0027). Serum CRP level was significantly higher in patients with exacerbation compared with those with no exacerbation (mean 47.8 ± 66.0 mg/L vs 13.05 ± 27.7 mg/L, respectively, P = 0.0063). The combination of CRP level above 3.12 mg/L and PPM growth in BAL was observed in 89.2% of patients with exacerbation compared with only 52.3% of patients without exacerbation (P = 0.0031).
CONCLUSIONS: ABC is common in severe COPD patients undergoing BLVR, and along with elevated CRP level both are associated with high risk of immediate post-procedural COPD exacerbation. These patients should be identified, carefully observed and possibly benefit from prophylactic microbiologically directed antibiotic treatment.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  COPD; bronchial colonization; exacerbation; lung volume reduction; postoperative respiratory infection; risk factors

Mesh:

Substances:

Year:  2014        PMID: 25196428     DOI: 10.1111/crj.12211

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  6 in total

Review 1.  Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease.

Authors:  Joseph Em van Agteren; Khin Hnin; Dion Grosser; Kristin V Carson; Brian J Smith
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

Review 2.  Lung volume reduction followed by lung transplantation-considerations on selection criteria and outcome.

Authors:  Alexis Slama; Christian Taube; Markus Kamler; Clemens Aigner
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

3.  New bacterial growth in bronchial secretions after bronchoscopic valve implantation.

Authors:  Nilab Sarmand; Daniela Gompelmann; Konstantina Kontogianni; Markus Polke; Felix Jf Herth; Ralf Eberhardt
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-02-08

Review 4.  Review of lung sealant technologies for lung volume reduction in pulmonary disease.

Authors:  Branislava Milenkovic; Sanja Dimic Janjic; Spasoje Popevic
Journal:  Med Devices (Auckl)       Date:  2018-06-27

5.  Lung Volume Reduction Followed by Lung Transplantation in Emphysema-A Multicenter Matched Analysis.

Authors:  Alexis Slama; Laurens J Ceulemans; Celia Hedderich; Panja M Boehm; Jan Van Slambrouck; Stefan Schwarz; Christelle M Vandervelde; Markus Kamler; Peter Jaksch; Dirk Van Raemdonck; Konrad Hoetzenecker; Clemens Aigner
Journal:  Transpl Int       Date:  2022-04-14       Impact factor: 3.842

Review 6.  A Systematic Review and Meta-Analysis of the Prevalence and Impact of Pulmonary Bacterial Colonisation in Stable State Chronic Obstructive Pulmonary Disease (COPD).

Authors:  Michael N Armitage; Daniella A Spittle; Alice M Turner
Journal:  Biomedicines       Date:  2021-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.